National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cabozantinib (Cabometyx®)

Cabozantinib (Cabometyx®) is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

NCPE Assessment Process Complete
Rapid review received 20/03/2017
Rapid review completed 25/04/2017
Rapid Review outcome Full pharmacoeconomic assessment
Full pharmacoeconomic assessment commissioned by HSE 02/05/2017
Pre-submission consultation with Applicant 17/07/2017
Submission received from Applicant 03/11/2017
Preliminary review sent to Applicant 24/01/2018
NCPE assessment re-commenced 27/04/2018
Factual accuracy sent to applicant 06/06/2018
NCPE assessment re-commenced 29/06/2018
NCPE assessment completed 03/07/2018
NCPE assessment outcome The NCPE recommends that cabozantinib (Cabometyx®) for the treatment of advanced or metastatic clear-cell RCC not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.


The HSE has approved reimbursement following confidential price negotiations January 2019.